These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 36597704)

  • 1. Application of immune checkpoint inhibitors in immunotherapy for gastric cancer.
    Wu YX; Zhou XY; Wang JQ; Chen GM; Chen JX; Wang RC; Huang JQ; Chen JS
    Immunotherapy; 2023 Feb; 15(2):101-115. PubMed ID: 36597704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in clinical immunotherapy for gastric cancer.
    Li K; Zhang A; Li X; Zhang H; Zhao L
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188615. PubMed ID: 34403771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advances in predictive biomarkers associated with immune checkpoint inhibitors for tumor therapy].
    Guo R; Li X; Hao M; Liang Y; Wang L; Yang Z
    Sheng Wu Gong Cheng Xue Bao; 2023 Apr; 39(4):1403-1424. PubMed ID: 37154314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
    Zeng Z; Yang B; Liao Z
    Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical significance of immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer].
    Zhu ZG
    Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(16):1331-1336. PubMed ID: 38644278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer.
    Han Z; Zhang Z; Yang X; Li Z; Sang S; Islam MT; Guo AA; Li Z; Wang X; Wang J; Zhang T; Sun Z; Yu L; Wang W; Xiong W; Li G; Jiang Y
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38749538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current management and biomarkers of immunotherapy in advanced gastric cancer.
    Chang X; Ge X; Zhang Y; Xue X
    Medicine (Baltimore); 2022 May; 101(21):e29304. PubMed ID: 35623069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the efficacy of immunotherapy in gastric cancer: Insights from immune checkpoint inhibitors.
    Yang YN; Wang LS; Dang YQ; Ji G
    World J Gastroenterol; 2024 Aug; 30(32):3726-3729. PubMed ID: 39221068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer.
    Wang KW; Wang MD; Li ZX; Hu BS; Wu JJ; Yuan ZD; Wu XL; Yuan QF; Yuan FL
    Front Immunol; 2022; 13():992060. PubMed ID: 36311733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapeutic advances in gastric cancer.
    Yoneda A; Kuroki T; Eguchi S
    Surg Today; 2021 Nov; 51(11):1727-1735. PubMed ID: 33590326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification : Immunoneoadjuvant therapy of gastric cancer.
    Yao G; Yuan J; Duan Q; Tan Y; Zhang Q; Chen D; Chen J
    Invest New Drugs; 2024 Feb; 42(1):1-13. PubMed ID: 37971628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of neoadjuvant immunotherapy for the treatment of gastric cancer.
    Zhang X; Liu B; Wang R; Li X; Zhou W
    Clin Transl Oncol; 2024 Sep; 26(9):2097-2108. PubMed ID: 38504071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of immunotherapy for advanced gastric cancer.
    Kawazoe A; Shitara K; Boku N; Yoshikawa T; Terashima M
    Jpn J Clin Oncol; 2021 Jan; 51(1):20-27. PubMed ID: 33241322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of immune checkpoint inhibitors for gastric cancer.
    Kono K; Nakajima S; Mimura K
    Gastric Cancer; 2020 Jul; 23(4):565-578. PubMed ID: 32468420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
    Yan Y; Wang X; Liu C; Jia J
    BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine signaling: Optimal target for gastric cancer immunotherapy.
    Wang J; Du L; Chen X
    Front Immunol; 2022; 13():1027838. PubMed ID: 36189223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice.
    Zouein J; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2022 Feb; 14(2):155-167. PubMed ID: 34865502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer.
    Li S; Yu W; Xie F; Luo H; Liu Z; Lv W; Shi D; Yu D; Gao P; Chen C; Wei M; Zhou W; Wang J; Zhao Z; Dai X; Xu Q; Zhang X; Huang M; Huang K; Wang J; Li J; Sheng L; Liu L
    Nat Commun; 2023 Jan; 14(1):8. PubMed ID: 36596787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.